AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 32729363
Drug: Antiviral drugs
RxNorm normalized name: antiviral drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiviral drugs (specific drugs not mentioned)
Trial: 32729363
Drug: Multi-drug combination
RxNorm normalized name: Parasedge Multi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multi-drug combination therapy
Trial: 32802264
Drug: NSDP plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NSDP plus supragingival irrigation with aerosolized 0.5% hydrogen peroxide (H2O2) solution
Trial: 32302347
Drug: Melatonin 20mg
RxNorm normalized name: melatonin 20 MG
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Melatonin 20mg before and during the first cycle of chemotherapy
Trial: 35154575
Drug: Silymarin (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silymarin (400 mg/day) along with DAAs (Sofosbuvir 400 mg/day and Ribavirin 800 mg/day) for 8 weeks
Trial: 35154575
Drug: DAAs (Sofosbuvir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DAAs (Sofosbuvir 400 mg/day and Ribavirin 800 mg/day)
Trial: 32618122
Drug: Gabapentin at
RxNorm normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gabapentin at 20 mg/kg per day
Trial: 34844816
Drug: Extracorporeal Shock
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Extracorporeal Shock Wave Therapy (ESWT) with 512 impulses of 0.15mJ/mm2, twice per week for 4 weeks
Trial: 34844816
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment for burn scars
Trial: 32845997
Drug: Intravenous N-Acetylcysteine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous N-Acetylcysteine (NAC)
Trial: 34978552
Drug: Lyophilized concentrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lyophilized concentrate of purple corn (Zea mays L.) 200 mg
Trial: 36125974
Drug: Extracorporeal Shockwave
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Extracorporeal Shockwave Therapy (ESWT) + Stretching Exercises (SEs)
Trial: 34267122
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin type A (BTA) injection
Trial: 33374687
Drug: Saline solution
RxNorm normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline solution (SS) injection
Trial: 33374687
Drug: Lidocaine (LD)
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine (LD) injection
Trial: 33443879
Drug: Post-treatment nasofrontal
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Post-treatment nasofrontal angle
Trial: 33443879
Drug: Post-treatment nasolabial
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Post-treatment nasolabial angle
Trial: 33443879
Drug: Actual dosage
RxNorm normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Actual dosage
Trial: 34371515
Drug: Continuous MMF
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous MMF treatment (control group)
Trial: 33666188
Drug: Bepotastine 1.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bepotastine 1.5% ophthalmic drops
Trial: 33666188
Drug: Olopatadine 0.1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olopatadine 0.1% ophthalmic drops
Trial: 33549312
Drug: Antibiotic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic therapy (oral levofloxacin 500 mg and tinidazole 1,000 mg daily for 14 days)
Trial: 33549312
Drug: Treatment arm
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment arm (attempted pregnancy)
Trial: 33549312
Drug: Treatment arm
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment arm (randomized subjects)
Trial: 33639839
Drug: Sugammadex 2
RxNorm normalized name: sugammadex 200 MG in 2 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugammadex 2 mg/kg ABW
Trial: 33639839
Drug: Sugammadex 2
RxNorm normalized name: sugammadex 200 MG in 2 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugammadex 2 mg/kg IBW
Trial: 33639839
Drug: Neostigmine 5
RxNorm normalized name: neostigmine 5 mg/5 mL preservative-free intravenous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neostigmine 5 mg and glycopyrrolate 1 mg
Trial: 33639839
Drug: Sugammadex 4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugammadex 4 mg/kg ABW
Trial: 33639839
Drug: Sugammadex 4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugammadex 4 mg/kg IBW
Trial: 33774169
Drug: 1000 mg
RxNorm normalized name: bran 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg of acetaminophen orally every 6 hours for 1 day prior to and after surgery, then every 8 hours during postoperative days 2-5, with the option to take 5 mg of oxycodone every 6 hours as needed after surgery.
Trial: 33774169
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg of oxycodone every 6 hours as needed and 1000 mg of acetaminophen orally every 6 hours as needed after surgery.
Trial: 33774169
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg of oxycodone every 6 hours as needed without any additional acetaminophen after surgery.
Trial: 34797431
Drug: Tapered implant
RxNorm normalized name: dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tapered implant (TI)
Trial: 34797431
Drug: Straight implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Straight implant (SI)
Trial: 32741354
Drug: Weekly iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly iron and folate supplement for adolescent girls
Trial: 32741354
Drug: Deworming programme
RxNorm normalized name: oxfendazole
DrugBank: Oxfendazole (DB11446)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deworming programme twice per year
Trial: 35325467
Drug: High-dose glucocorticoid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose glucocorticoid (10 mg/kg methylprednisolone)
Trial: 35325467
Drug: Low-dose glucocorticoid
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose glucocorticoid (8 mg dexamethasone)
Trial: 32882163
Drug: Prasugrel 5
RxNorm normalized name: prasugrel 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prasugrel 5 mg after 1 month of 10 mg prasugrel plus 100 mg aspirin daily (de-escalation group)
Trial: 32882163
Drug: Prasugrel 10
RxNorm normalized name: prasugrel 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prasugrel 10 mg plus 100 mg aspirin daily (conventional group)
Trial: 32882163
Drug: Prasugrel-based de-escalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prasugrel-based de-escalation therapy
Trial: 33887247
Drug: Adjunctive host-directed
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjunctive host-directed therapies
Trial: 32535263
Drug: Edaravone (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edaravone (0.5 mg/kg intravenous after induction of anesthesia)
Trial: 32881586
Drug: Endobronchial valve
RxNorm normalized name: VALVE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endobronchial valve treatment
Trial: 35617211
Drug: Subtenon triamcinolone
RxNorm normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subtenon triamcinolone acetonide (TAAC) injection (4mg) with MMC‐TRAB
Trial: 36458119
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual + aerobic exercise training (40-min twice a week for 8 weeks)
Trial: 36458119
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual + aerobic exercise training
Trial: 32576199
Drug: ENG-releasing subdermal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ENG-releasing subdermal contraceptive implant
Trial: 32451288
Drug: Sublingual immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual immunotherapy (SLIT) plus pharmacotherapy on demand
Trial: 32978352
Drug: 0.5% bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% bupivacaine solution
Trial: 34998000
Drug: Intralesional MMR
RxNorm normalized name: varicella-zoster virus vaccine live (Oka-Merck) strain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intralesional MMR injections
Trial: 34998000
Drug: Intralesional BCG
RxNorm normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intralesional BCG injection
Trial: 34998000
Drug: Intralesional candida
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intralesional candida antigen injection
Trial: 34033939
Drug: scaling and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: scaling and root planing with indocyanine green-based antimicrobial photodynamic therapy (perio-green, 0.1 mg/ml)
Trial: 34033939
Drug: scaling and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: scaling and root planing with indocyanine green-based antimicrobial photodynamic therapy
Trial: 34464752
Drug: Multimodal prehabilitation
RxNorm normalized name: GLUTATHIONE 12.5 g in 100 mL ORAL LIQUID [K2LTS Brain Rehabilitation]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multimodal prehabilitation combining a mixed-nutrient supplement with structured supervised and home-based exercise training, and relaxation strategies (Prehab)
Trial: 32338106
Drug: Low-dose SPN-810
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose SPN-810 (12/18 mg/day)
Trial: 32338106
Drug: Medium-dose SPN-810
RxNorm normalized name: Medium-Chain Triglycerides
DrugBank: Medium-chain triglycerides (DB13959)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium-dose SPN-810 (24/36 mg/day)
Trial: 32338106
Drug: High-dose SPN-810
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose SPN-810 (36/54 mg/day)
Trial: 33185468
Drug: 6.25 mg
RxNorm normalized name: captopril 6.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6.25 mg SHP465 mixed amphetamine salts (MAS) once daily
Trial: 32902413
Drug: Baricitinib (JAK
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baricitinib (JAK inhibitor)
Trial: 32142492
Drug: Hydromorphone 0.05
RxNorm normalized name: HYDROMORPHONE 0.05MG/BUPIVACAINE 0.1%/ML/NS INJ,BAG,200ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydromorphone 0.05 mg/mL + nalbuphine 0.5 mg/mL (group LN)
Trial: 32142492
Drug: Hydromorphone 0.05
RxNorm normalized name: HYDROMORPHONE 0.05MG/BUPIVACAINE 0.1%/ML/NS INJ,BAG,200ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydromorphone 0.05 mg/mL + nalbuphine 0.7 mg/mL (group MN)
Trial: 32142492
Drug: Hydromorphone 0.05
RxNorm normalized name: HYDROMORPHONE 0.05MG/BUPIVACAINE 0.1%/ML/NS INJ,BAG,200ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydromorphone 0.05 mg/mL + nalbuphine 0.9 mg/mL (group HN)
Trial: 34695525
Drug: Ticagrelor 60
RxNorm normalized name: ticagrelor 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ticagrelor 60 mg twice daily
Trial: 32321518
Drug: Once-daily indacaterol/glycopyrronium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily indacaterol/glycopyrronium (IND/GLY) 110/50 μg
Trial: 32321518
Drug: Twice-daily salmeterol/fluticasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice-daily salmeterol/fluticasone (SFC) 50/500 μg
Trial: 38880172
Drug: Systemic adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic adjuvant therapy
Trial: 33139143
Drug: Multifaceted stewardship
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multifaceted stewardship intervention including education on guideline-based treatment, tests of antimicrobial treatment, implementation of a clinical treatment algorithm, and audit and feedback.
Trial: 32717068
Drug: Oral bisphosphonates
RxNorm normalized name: methylene diphosphonate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral bisphosphonates (oBP)
Trial: 33167078
Drug: Vitamin A
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin A absorption (retinyl palmitate) after soymilk consumption (501 IU vitamin A)
Trial: 33167078
Drug: Vitamin D2
RxNorm normalized name: vitamin D2
DrugBank: Ergocalciferol (DB00153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin D2 absorption after soymilk consumption (119 IU vitamin D2)
Trial: 32586394
Drug: High-Dose LMWH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-Dose LMWH (Enoxaparin 70 IU/kg twice daily)
Trial: 32586394
Drug: Low-Dose LMWH
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-Dose LMWH (Enoxaparin 4000 IU once daily)
Trial: 32586394
Drug: High-Dose LMWH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-Dose LMWH
Trial: 32586394
Drug: Low-Dose LMWH
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-Dose LMWH
Trial: 35421217
Drug: Integrated agricultural
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Integrated agricultural intervention including distribution of micronutrient powders (MNP), poultry, seeds of greens and onions, soap and chlorine solution, and monthly behavior change trainings.
Trial: 33914660
Drug: ANS +
RxNorm normalized name: Aldex AN
DrugBank: Doxylamine (DB00366)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ANS + CARN (20 mg/kg body weight)
Trial: 32013882
Drug: Pb1 (2000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pb1 (2000 mg/kg Pb (NO3)2)
Trial: 32013882
Drug: Pb2 (10,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pb2 (10,000 mg/kg Pb (NO3)2)
Trial: 35971859
Drug: Family-based behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Family-based behavioural obesity treatment (FBT)
Trial: 33571040
Drug: Sambucus ebulus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sambucus ebulus L.
Trial: 34997178
Drug: 300 mg/day
RxNorm normalized name: alpelisib 300 mg/day (150 mg x 2) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg/day ALA
Trial: 33053078
Drug: 1.2g of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.2g of ginger daily for 90 days
Trial: 33053078
Drug: 1.2g of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.2g of placebo daily for 90 days
Trial: 38940494
Drug: Direct oral
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Direct oral anticoagulants
Trial: 34129960
Drug: Antimalarial drugs
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Antimalarial drugs (quinine, artemisinin combination therapies, and multiple drug combinations)
Trial: 34129960
Drug: Artemisinin combination
RxNorm normalized name: artemisinin
DrugBank: Artemisinin (DB13132)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artemisinin combination therapies
Trial: 34129960
Drug: Multiple drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple drug combinations
Trial: 34129960
Drug: Randomized trials
RxNorm normalized name: jojoba oil, randomized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Randomized trials evaluating drug safety
Trial: 36465660
Drug: Dim Red
RxNorm normalized name: acid red 35
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dim Red Light + Placebo Capsules
Trial: 34310730
Drug: No EPO
RxNorm normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: No EPO treatment
Trial: 36394750
Drug: polyethylene glycol
RxNorm normalized name: Polyethylene Glycol
DrugBank: Polyethylene glycol (DB09287)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: polyethylene glycol loxenatide injection + metformin
Trial: 34175572
Drug: Treatment group
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment group (provided balanced information about ethical dilemmas)
Trial: 33203625
Drug: PQT (esomeprazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PQT (esomeprazole 20 mg, amoxicillin 1 g, clarithromycin 500 mg, polaprezinc 75 mg)
Trial: 33203625
Drug: Bismuth-containing quadruple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bismuth-containing quadruple therapy (esomeprazole 20 mg, amoxicillin 1 g, clarithromycin 500 mg, bismuth potassium citrate 220 mg)
Trial: 34882169
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg of armodafinil
Trial: 34882169
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg of armodafinil
Trial: 32444553
Drug: Multimodal lifestyle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multimodal lifestyle intervention (INT) including bright light therapy (BLT), physical activity (PA), and sleep hygiene education
Trial: 32488989
Drug: Sapanisertib 30
RxNorm normalized name: SAPANISERTIB
DrugBank: Sapanisertib (DB11836)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sapanisertib 30 mg once weekly
Trial: 36146944
Drug: Sapanisertib 4
RxNorm normalized name: SAPANISERTIB
DrugBank: Sapanisertib (DB11836)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sapanisertib 4 mg plus TAK-117 200 mg, both once daily for 3 days/week
Trial: 35813435
Drug: Sandplay therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sandplay therapy (8 individual box court game tutoring sessions, once a week)
Trial: 34378869
Drug: Sandplay therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sandplay therapy
Trial: 616743266
Drug: Being on
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Being on antiretroviral therapy at first antenatal care booking
Trial: 32801342
Drug: l-DOPA 100/25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: l-DOPA 100/25 mg
Trial: 32801342
Drug: l-DOPA 200/50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: l-DOPA 200/50 mg
Trial: 32481262
Drug: Successful clinical
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Successful clinical outcome (SCO) defined as significant improvement in 2 of 3 of L-vas, R-vas, or ODI score at follow-up
Trial: 35922251
Drug: Cemiplimab (350
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cemiplimab (350 mg intravenously every 3 weeks)
Trial: 38959480
Drug: Chemotherapy (investigator's
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (investigator's choice)
Trial: 32542515
Drug: Neuronavigated rTMS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neuronavigated rTMS (10 Hz, 90% of resting motor threshold, 1,600 pulses over 20 min twice per day) for five days
Trial: 36721157
Drug: Saline injection
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline injection (Control)
Trial: 33528092
Drug: Topical acidified
RxNorm normalized name: Acidifiers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical acidified aliphatic ester
Trial: 35882474
Drug: HFL treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HFL treatment
Trial: 35882474
Drug: Dual, HFL,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual, HFL, and RF treatments
Trial: 32276098
Drug: PALO 0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PALO 0.25 mg IV infusion (30-minute infusion)
Trial: 32276098
Drug: PALO 0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PALO 0.25 mg IV bolus (30-second bolus)
Trial: 32420357
Drug: KIR3DL1-HLA-Bw4 combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KIR3DL1-HLA-Bw4 combination
Trial: 34552329
Drug: OMACOR (OM3EE)
DrugBank: Omega-3-acid ethyl esters (DB09539)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OMACOR (OM3EE) 2 g/day for 4 weeks, then 4 g/day for 8 weeks
Trial: 34164754
Drug: Surgical drill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical drill guide with implant insertion guide (SDIG)
Trial: 34455631
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of β‐NAG2 lotion for 8 weeks
Trial: 32689617
Drug: Combination (joint
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination (joint mobilization and active stretching)
Trial: 36501060
Drug: p-synephrine (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: p-synephrine (3 mg/kg)
Trial: 36501060
Drug: Placebo (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (3 mg/kg cellulose)
Trial: 32141627
Drug: Statin use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statin use (dose intensity analysis) 6 months post-diagnosis
Trial: 36368598
Drug: Reduction in
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reduction in deep subcutaneous adipose tissue (dSAT)
Trial: 32577886
Drug: Vitamin B
RxNorm normalized name: VITAMIN B
DrugBank: Inositol (DB13178)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin B complex supplements
Trial: 35405933
Drug: 5 g/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 g/kg body mass (BM)/d
Trial: 35405933
Drug: 7 g/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7 g/kg body mass (BM)/d